Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through γδ T-cell IL-17 production in a murine model of sepsis

Kevin R. Kasten  
*University of Cincinnati - Main Campus*

Priya S. Prakash  
*University of Cincinnati - Main Campus*

Jacqueline Unsinger  
*Washington University School of Medicine in St. Louis*

Holly S. Goetzman  
*University of Cincinnati - Main Campus*

Lisa G. England  
*University of Cincinnati - Main Campus*

*See next page for additional authors*

Follow this and additional works at: [https://digitalcommons.wustl.edu/open_access_pubs](https://digitalcommons.wustl.edu/open_access_pubs)  
Please let us know how this document benefits you.

**Recommended Citation**  
Kasten, Kevin R.; Prakash, Priya S.; Unsinger, Jacqueline; Goetzman, Holly S.; England, Lisa G.; Cave, Cindy M.; Seitz, Aaron P.; Mazuski, Cristina N.; Zhou, Tony T.; Morre, Michel; Hotchkiss, Richard S.; Hildeman, David A.; and Caldwell, Charles C., "Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through γδ T-cell IL-17 production in a murine model of sepsis." Infection and Immunity. 78, 11. 4714-4722. (2010).  
[https://digitalcommons.wustl.edu/open_access_pubs/2493](https://digitalcommons.wustl.edu/open_access_pubs/2493)

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Authors
Interleukin-7 (IL-7) Treatment Accelerates Neutrophil Recruitment through γδ T-Cell IL-17 Production in a Murine Model of Sepsis


Updated information and services can be found at:
http://iai.asm.org/content/78/11/4714

These include:

REFERENCES
This article cites 59 articles, 26 of which can be accessed free at: http://iai.asm.org/content/78/11/4714#ref-list-1

CONTENT ALERTS
Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more»

Information about commercial reprint orders: http://journals.asm.org/site/misc/reprints.xhtml
To subscribe to another ASM Journal go to: http://journals.asm.org/site/subscriptions/
Interleukin-7 (IL-7) Treatment Accelerates Neutrophil Recruitment through γδ T-Cell IL-17 Production in a Murine Model of Sepsis

Kevin R. Kasten, 1 Priya S. Prakash, 1 Jacqueline Unsinger, 2 Holly S. Goetzman, 1 Lisa G. England, 1 Cindy M. Cave, 1 Aaron P. Seitz, 1 Cristina N. Mazuski, 2 Tony T. Zhou, 3 Michel Morre, 3 Richard S. Hotchkiss, 2 David A. Hildeman, 4 and Charles C. Caldwell 1*

Division of Research, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio; 1; Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri; 2; Cytheris Corporation, Issy-les-Moulineaux, France; 3, and Department of Immunobiology, Cincinnati Children's Hospital, Cincinnati, Ohio 4

Received 3 May 2010/Returned for modification 17 June 2010/Accepted 20 August 2010

The sepsis syndrome represents an improper immune response to infection and is associated with unacceptably high rates of mortality and morbidity. The interactions between T cells and the innate immune system while combating sepsis are poorly understood. In this report, we observed that treatment with the potent, anti-apoptotic cytokine interleukin-7 (IL-7) accelerated neutrophil recruitment and improved bacterial clearance. We first determined that T cells were necessary for the previously observed IL-7-mediated enhanced survival. Next, IL-7 increased Bcl-2 expression in T cells isolated from septic mice as early as 3 h following treatment. This treatment resulted in increased gamma interferon (IFN-γ) and IP-10 production within the septic peritoneum together with local and systemic increases of IL-17 in IL-7-treated mice. We further demonstrate that the increase in IL-17 was largely due to increased recruitment and production by γδ T cells, which express CXCR3. Consistent with increased IL-17 production, IL-7 treatment increased CXCL1/KC production, neutrophil recruitment, and bacterial clearance. Significantly, end-organ tissue injury was not significantly different between vehicle- and IL-7-treated mice. Collectively, these data illustrate that IL-7 can mediate the cross talk between Th1 and Th17 lymphocytes during sepsis such that neutrophil recruitment and bacterial clearance is improved while early tissue injury is not increased. All together, these observations may underlay novel potential therapeutic targets to improve the host immune response to sepsis.

Sepsis entails a complex immune process involving both the innate and adaptive immune systems, which can effect concurrent changes on the host (39, 56). The immune response to infection is typically modeled by phagocytic cells as first responders for the early removal of pathogenic bodies, while the adaptive system becomes involved later for mop-up duty and maintenance of a long-term immune response against the current pathogens. Recent literature suggests an early role for the adaptive immune system in mediating sepsis (30); however, a paucity of effective sepsis therapies suggests a gap in our knowledge concerning cross talk and the respective roles of the adaptive and innate immune during the host response to sepsis. An increased understanding of the complex interplay of these immune response arms is critical, given the annual toll this diagnosis places on both human life and health care dollars (2, 41).

γδ T cells represent a small subset of cells with a restricted T-cell receptor (TCR) repertoire of ligands. These cells are widespread in epithelium-rich tissues such as the skin and intestine, with cytokine production dictated by the tissues in which they reside (8, 12, 20, 40, 54). Contradictory results have been published on the role of γδ T cells during sepsis, suggesting that these cells become more pathogenic as the severity of the sepsis model used increases (6, 10, 13). Our previous report demonstrates that γδ T cells play a key role in neutrophil recruitment to the site of infection and control of bacterial load following cecal ligation and puncture (CLP). Recently, γδ T cells have been implicated as the major producer of the cytokine interleukin-17 (IL-17) during sepsis (13). IL-17A is part of the IL-17 family of cytokines, produced by diverse cell populations such as conventional CD4 and CD8 T cells as well as γδ T cells (58). While the protective or pathogenic role of IL-17 in sepsis is not yet clear (13, 16), it is known that IL-17 mediates recruitment of myeloid cells through downstream production of CXCL1/KC and CXCL2/MIP-2, presumably through the stabilization of mRNA (18). Additionally, the IL-17 receptor (IL-17R) is necessary for neutrophil recruitment to the site of infection and control of bacterial load following CLP (16). The functions of IL-17 on myeloid cell recruitment, along with its production by T cells during sepsis, make this cytokine an interesting target in mediating the cross talk that occurs between the innate and adaptive responses to sepsis.

The suggestion of early cross talk between the innate and adaptive immune responses extends from recent reports, indicating the necessity of T cells in bacterial clearance following infection (29, 37, 54, 55). Additionally, T-cell activation was newly linked to bacterial clearance through increased neutrophil oxidative burst and phagocytosis (29). These findings provide a bridge to the literature, demonstrating worsened outcomes in septic T-cell-deficient mice (25, 47). Further, it is known that T cells undergo apoptosis within the first 24 h after onset of sepsis (25, 27, 57), and the degree of apoptosis correlates with
the sepsis severity (24, 33). Additionally, remaining T cells demonstrate reduced functionality illustrated by decreased production of gamma interferon (IFN-γ) (28). Taken together, these results provide mechanistic insight into how prevention of T-cell apoptosis improves survival in a murine model of sepsis (26) and illustrate a therapeutic avenue for reduction of morbidity and mortality associated with this disease process.

The cytokines IL-2, IL-7, and IL-15 are ligands for the cytokine receptor common gamma chain. The IL-7 receptor is expressed mainly on T lymphocytes, with IL-7 playing a key role in T-cell differentiation, survival, and proliferation (36). Recently, we observed that IL-7 treatment significantly reduced T-cell apoptosis in the spleen and mesenteric lymph nodes following sepsis (55). Additionally, we reported that treatment with recombinant human IL-7 (rhIL-7) improved the delayed-type hypersensitivity (DTH) response while partially preventing a sepsis-induced decrease in T-cell IFN-γ production (55). The attenuation of T-cell apoptosis and improved functionality following rhIL-7 treatment were associated with improved survival (55). To build upon our previous study, we undertook investigations to further determine how IL-7 stabilization of T-cell numbers and function mediated tissue injury, bacterial load, and the neutrophil response during sepsis. Here, we found that IL-7 treatment significantly accelerated γδ T-cell recruitment to the site of infection, such that the bacterial load was decreased. Significantly, we postulate that the early IL-7 stabilization of the adaptive immune response allows for a more beneficial innate immune response during sepsis.

**MATERIALS AND METHODS**

Cecal ligation and puncture. Male C57BL/6 (wild-type [WT]) mice between 6 and 8 weeks of age (20 to 28 g), TCRα/β-/-/H9251/H9252-deficient mice (B6.129P2-Tcrdtm1Mom/J; Jackson Laboratory, Bar Harbor, ME), and TCRα-deficient mice (B6.129P2-Tcrdtm1Mom/J; Jackson Laboratory) were utilized. 3 weeks of age (20 to 28 g), TCRα/H9251/H9252-deficient mice (B6.129P2-Tcrdtm1Mom/J; Jackson Laboratory) were utilized. 49801; R&D, Minneapolis, MN), Bcl-2 (clone 3F11; BD Biosciences), IL-17A (clone RM4-5; BioLegend, San Diego, CA), CD69 (clone H1.2F3; BD Biosciences), CD44 (clones Pgp-1 and Ly-24; BD Biosciences), CD2L2 (clone MEL-14; Invitrogen, Carlsbad, CA), γδ T cell (clone H57-597), γδ T cell (clone GL3; BioLegend), CXCR3 (clone 49801; R&D, Minneapolis, MN), BL-2 clone (3F11; BD Biosciences), IL-17A (clone TC11-18H10.1; BioLegend), CD11b (clone M1/70; BD Biosciences), and Gr-1/Ly6G (clone 1A8; BD Biosciences). Leukocyte subsets were defined as follows: CD4+ naïve (CD62Lhi CD44lo), CD4+ central memory (CD62Llo CD44hi), CD4+ effector memory (CD62Llo CD44hi), CD8+ naïve (CD62Llo CD44hi), CD8+ central memory (CD62Lhi CD44hi), CD8+ effector memory (CD62Llo CD44hi), and neutrophils (Gr-1hi CD11b+).

**Bacterial load determination.** Bacterial load determination was performed with blood samples harvested aseptically by cardiac puncture as previously described (54). Samples were serially diluted in sterile saline and cultured on tryptic soy agar plate. Plates were incubated at 37°C for 24 h, and colony enumeration was performed.

**Cytokine and chemokine measurements by ELISA.** Whole-blood samples were harvested by sterile cardiac puncturing, and sera were isolated using serum separator tubes. Peritoneal lavage fluid and cells were obtained by injection of 9 ml 0.9% normal saline intraperitoneally and removal via syringe. IL-6 (Invitrogen), IFN-γ (Invitrogen), CXCL1/KC (R&D), IL-17 (eBioscience, San Diego, CA), and CXCL10/IP-10 (Peprotech, Rocky Hill, NJ) levels were analyzed by enzyme-linked immunosorbent assay (ELISA), according to the manufacturers’ protocol.

**Phagocytosis determination.** Cells from peritoneal lavage fluid were harvested 24 h after CLP and mixed with opsonized Alexa Fluor 488-labeled Esherichia coli (K-12 strain; Invitrogen). This suspension was incubated at 37°C for 5 min. This time point was chosen based upon previous optimization experiments. Following the incubation period, unattached extracellular bacteria were removed by being washed three times. Samples were run on a Becton Dickinson LSR II to determine the mean fluorescence intensity (MFI), a measure of the number of bacteria taken up per cell. To quench the fluorescence of adherent bacteria, trypan blue was added 1 min before the second acquisition. Quenching with trypan blue reduced the fluorescein isothiocyanate (FITC) fluorescence of adherent bacteria by excitation energy transfer (21).

**Neutrophil oxidative burst assay.** The oxidative burst was determined as previously described (48). Briefly, polystyrene tissue culture dishes were coated with 1 μg/well fibronectin for 2 h at 37°C and 5% CO2 and then washed. A total of 100 μl of reaction mixture (10 mM scopolin, 1 mg/ml horseradish peroxydase, 4 mM NaF in Krebs-Ringer phosphate buffer [KRPG]) and 20 μl neutrophils resuspended in KRPG at 7.5 × 106 cells/ml were allowed to incubate for 10 min at 37°C in the wells prior to stimulation with either buffer or N-formyl-methionyl-leucyl-phenylalanine (FMLP; 100 nM). Fluorescence was measured immediately and at 10-min intervals for 60 min. H2O2 production was calculated from the decrease in fluorescence due to oxidation of scopoletin. The data are expressed as nanomoles of H2O2 produced per 1.5 × 106 polymorphonuclear leukocytes (PMNs).

**Tissue injury determination.** For general tissue damage assessment, serum samples were obtained as described above, diluted 1:4, and run for the aspartate transaminase (AST) level on the Siemens Dimension Xpand Plus integrated chemistry system (Siemens Healthcare Diagnostics, Deerfield, IL). Lung tissue (100 mg) was homogenized in 2 ml buffer A (3.4 mM KH2PO4 and 16 mM Na2HPO4, pH 7.4). After centrifugation for 20 min at 10,000 × g, the pellet was resuspended in 10 vol buffer B (45.2 mM KH2PO4, 6.5 mM Na2HPO4, 10 mM EDTA, and 0.5% hexadecyltrimethylammonium, pH 6.0) and sonicated for 10 min. After being heated for 2 h at 60°C, the supernatant was reacted with 3,3’,5,5’-tetramethylbenzidine (Sigma Chemical Co., St. Louis, MO), and the optical density (OD) at 655 nm was determined. Two-centimeter sections of intestine were harvested and placed on previously weighed trays. Samples were incubated at 55°C for 72 h and reweighed. They were incubated for another 24 h at 55°C and reweighed to ensure complete fluid evacuation. The wet weight-to-dry weight ratio was then calculated.

**Statistical analyses.** Statistical comparisons were performed using the Kaplan-Meier log rank test (survival), Student t test (two groups), or one-way analysis of variance (ANOVA) with the Holm-Sidak post hoc test (more than two groups), using StatView 5.5 (SAS Institute, Cary, NC) and GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA). The mean and standard error of the mean were calculated in experiments containing multiple data points. A P value of <0.05 was considered statistically significant.

## RESULTS

**Previously,** we demonstrated enhanced survival in septic wild-type mice treated with recombinant human IL-7 at the time of CLP (54). To confirm the requirement for γδ and γδ T cells for the rhIL-7-mediated survival advantage during sepsis, we subjected mice deficient in these cells treated with either rhIL-7 or vehicle and then monitored them for survival. Here, we observed no differences in survival or median survival
times (Fig. 1). All together, these data implicate the necessity of $\alpha\beta$ and/or $\gamma\delta$ T cells for the IL-7-induced increase in survival of septic wild-type mice.

A signature hallmark of sepsis is the profound and rapid depletion of lymphocytes (23). T-cell apoptosis has been reported as the underlying cause of decreased lymphocyte numbers following sepsis (27, 60). Previously, we observed that splenic T cells isolated from rhIL-7-treated mice had increased Bcl-2 expression as well as reduced T-cell apoptosis at 24 h after CLP. As increased expression of Bcl-2 at 24 h after CLP may represent a selection bias of surviving lymphocytes, we sought to elucidate the effect of rhIL-7 on T-cell Bcl-2 expression at 3 h after sepsis induction, when cells have not yet undergone significant depletion. Here, we determined that IL-7 treatment resulted in increased Bcl-2 expression in naive CD4 and CD8 T cells and effector memory CD4 T cells compared to that in T cells isolated from vehicle-treated septic mice (Fig. 2A to D). Thus, rhIL-7 treatment can begin to enhance T-cell survival quite early after treatment.

IL-7 treatment enhances IFN-γ and IP-10 production during sepsis. IFN-γ is a key cytokine in the host immune re-
response to sepsis, as evidenced by decreased survival of IFN-γ knockout mice subjected to CLP compared to that of WT mice (37). Here, we observed increased peritoneal IFN-γ concentrations in rhIL-7-treated mice at almost double the level found in vehicle-treated animals (Fig. 3). Sham levels were undetectable, as were serum levels of IFN-γ at this time point (data not shown). Of the many roles IFN-γ can play during the immune response, one involves stimulating the release of CXCL10/IP-10 by macrophages (52). CXCL10/IP-10 is one ligand for CXCR3. It has been previously reported that γδ T cells can express CXCR3 and that this receptor can mediate recruitment (1). Therefore, we evaluated the CXCR3 ligand in WT mice following CLP and observed its expression upon 89% of peritoneal γδ T cells (Fig. 4A). Additionally, we demonstrated an approximately 2-fold increase in CXCL10/IP-10 in the rhIL-7-treated mice versus that in the vehicle-treated mice, while sham mice had no appreciable levels of this ligand (Fig. 4B). Thus, rhIL-7 treatment, possibly through prevention of T-cell apoptosis, enhances peritoneal levels of IFN-γ with a subsequent downstream increase in CXCL10/IP-10 production.

Neutrophil recruitment, but not activation or functionality, is accelerated by rhIL-7 treatment. Neutrophils clear bacterial pathogens during sepsis as part of a complex process involving recruitment to the site of infection, activation, cytokine secretion, phagocytosis, and oxidative burst killing of bacteria. Here, we evaluated the enumeration, activation, and functionality of neutrophils found at the site of infection at multiple time points following CLP. Treatment of mice with rhIL-7 caused an accelerated recruitment to the peritoneum at 6 h following CLP compared to that of vehicle-treated mice, with no difference between groups seen at 24 h (Fig. 5A). CD11b expression was used as a surrogate marker for neutrophil activation and

FIG. 4. CXCR3 expression on peritoneal TCR γδ cells. (A) Flow cytometric analysis of WT peritoneal TCR γδ cells obtained 3 h following CLP-evaluated CXCR3 expression. The sample size was 4 mice/group. (B) Sham- and CLP-operated WT mice were treated with 5 μg human recombinant IL-7 or vehicle at the time of CLP. Peritoneal lavage fluid obtained 3 h after CLP was analyzed by ELISA for CXCL10/IP-10. The sample size was 4 mice/group. Data are expressed as the mean values ± SEM. **, P < 0.01 compared to sham groups; &, P < 0.01 compared to all groups; PE-A, phycoerythrin; APC-A, allophycocyanin.

FIG. 5. IL-7 treatment enhances neutrophil recruitment but not activation or functionality during sepsis. CLP-operated WT mice were treated with 5 μg human recombinant IL-7 or vehicle at the time of CLP. Neutrophils at the site of infection were analyzed by flow cytometry for enumeration (A) and determination of CD11b expression (B) at the indicated times following CLP. The sample size was 9 to 13 mice/group at 6 h and 12 to 13 mice/group at 24 h. Neutrophil functionality was evaluated using phagocytosis (C) and oxidative burst (D) at the indicated time points. The sample size was 6 mice/group at 3 h and 4 mice/group at 6 h. Data are expressed as the mean values ± SEM. **, P < 0.01.
significantly elevated IL-17 only in WT mice treated with neal lavage fluid at 6 h following the injury demonstrated with and without rhIL-7 treatment. Evaluation of the peritoneal numbers of IL-17-producing peritoneal significant producers of IL-17 (13) and can play a critical role CXCL1/KC. During sepsis, can be mediated by IL-17 and subsequent production ofduction, and CXCL1/KC production.

During sepsis, we subjected wild-type and H9253/H9254 H9253/H9254 IL-17 production (Fig. 6A and B). To confirm the necessity of H9262 H9253/H9254 expression by peritoneal H9253/H9254 of CLP. Flow cytometric analysis was used to enumerate the number of peritoneal γδ T cells producing IL-17 (A) and the intensity of IL-17 expression by peritoneal γδ T cells (B) 3 h after CLP. The sample size was 4 mice/group. (C) Peritoneal lavage fluid obtained 6 h after CLP from WT and TCR γδ-deficient mice treated with IL-7 or vehicle was analyzed by ELISA for IL-17. The sample size was 5 mice/group. (D) Peritoneal lavage fluid obtained 6 h after CLP was analyzed by ELISA for CXCL1/KC. The sample size was 11 to 14 mice/group. Data are expressed as the mean values ± SEM. *, P < 0.05; **, P < 0.01.

showed no difference between WT and rhIL-7-treated mice at 6 or 24 h following CLP (Fig. 5B) or between sham animals treated with rhIL-7 and phosphate-buffered saline (PBS) (data not shown). Lastly, we evaluated the phagocytosis and oxidative burst potential of neutrophils obtained from the site of infection at 6 h and 24 h following CLP in WT and rhIL-7-treated mice. Interestingly, we found no differences in either phagocytosis (Fig. 5C) or oxidative burst (Fig. 5D) between the two groups at either time point. These findings suggest that rhIL-7 plays a singular role in neutrophil recruitment to the site of infection during sepsis.

rhlL-7 treatment increased γδ T-cell numbers, IL-17 production, and CXCL1/KC production. Neutrophil recruitment can be mediated by IL-17 and subsequent production of CXCL1/KC. During sepsis, γδ T cells have been reported to be significant producers of IL-17 (13) and can play a critical role in increasing peritoneal neutrophil accumulation (54). In pilot experiments, we were unable to observe significant numbers of peritoneal γδ T cells in sham animals. Following CLP, we determined that rhIL-7 treatment resulted in both increasing the numbers of IL-17-producing γδ T cells and enhancing IL-17 production (Fig. 6A and B). To confirm the necessity of γδ T cells for IL-7-induced enhancement of IL-17 during sepsis, we subjected wild-type and γδ T-cell-deficient mice to CLP with and without rhIL-7 treatment. Evaluation of the peritoneal lavage fluid at 6 h following the injury demonstrated significantly elevated IL-17 only in WT mice treated with rhIL-7 compared to that in all other treatment groups (Fig. 6C). Lastly, a positive correlation between neutrophil recruitment and CXCL1/KC expression has been reported (17, 34, 44, 51, 59). As IL-7 treatment increased neutrophil numbers at the site of infection, we next evaluated local levels of CXCL1/KC and observed significantly increased CXCL1/KC in the peritoneal lavage fluid of rhIL-7-treated mice compared to that in the peritoneal lavage fluid of WT mice (Fig. 6D). Thus, treatment with rhIL-7 rapidly increases the number of peritoneal γδ T cells present following sepsis, the production of IL-17 by these cells, and increased CXCL1/KC accumulation.

rhlL-7 treatment increases inflammation and bacterial clearance without changing end-organ tissue injury. Properly regulated neutrophils play an important role in bacterial clearance (32); however, decreased apoptosis and increased half-life may result in increased tissue injury during sepsis (22). During sepsis, an optimal balance among early pathogen clearance, associated inflammation, and end-organ tissue damage will likely allow for a reduction of host morbidity and mortality. As IL-6 has previously been utilized as a surrogate marker for inflammation (42), we evaluated the serum levels of this cytokine at 6 and 24 h. Mice treated with rhIL-7 had significantly higher serum IL-6 levels at 6 h than WT mice, with no difference existing at 24 h (Fig. 7A). Evaluation of bacteremia at 24 h following CLP demonstrated a significantly lower bacterial load in those animals treated with rhIL-7 rather than vehicle (Fig. 7B), consistent with previous findings. We next evaluated general, lung, and intestine tissue injury. We observed that serum aspartate aminotransferase (AST) levels (Fig. 7C), lung myeloperoxidase (MPO) levels (Fig. 7D), bronchoalveolar lavage (BAL) fluid protein content (data not shown), and intestinal wet/dry ratios (Fig. 7E) were not significantly different between vehicle-treated WT mice and those treated with rhIL-7. Experiments conducted with sham-operated mice did not demonstrate detectable levels of IL-6, bacteremia, or tissue injury. All together, mice treated with rhIL-7 had diminished bacteremia and early increased, but not sustained, inflammation, but not worsened tissue damage, compared to those of vehicle-treated mice.

DISCUSSION

In this study, we tested the hypothesis that IL-7, a potent T-cell antiapoptotic cytokine, would mediate the early innate immune response to sepsis. First, we demonstrated the necessity of αβ and/or γδ T cells for the IL-7-induced increase in survival of septic wild-type mice. Additionally, we show the upregulation of Bcl-2 expression on CD4 T cells and/or γδ T cells following sepsis, the production of IL-17 by these cells, and increased CXCL1/KC accumulation. rhIL-7 treatment increases inflammation and bacterial clearance without changing end-organ tissue injury. Properly regulated neutrophils play an important role in bacterial clearance (32); however, decreased apoptosis and increased half-life may result in increased tissue injury during sepsis (22). During sepsis, an optimal balance among early pathogen clearance, associated inflammation, and end-organ tissue damage will likely allow for a reduction of host morbidity and mortality. As IL-6 has previously been utilized as a surrogate marker for inflammation (42), we evaluated the serum levels of this cytokine at 6 and 24 h. Mice treated with rhIL-7 had significantly higher serum IL-6 levels at 6 h than WT mice, with no difference existing at 24 h (Fig. 7A). Evaluation of bacteremia at 24 h following CLP demonstrated a significantly lower bacterial load in those animals treated with rhIL-7 rather than vehicle (Fig. 7B), consistent with previous findings. We next evaluated general, lung, and intestine tissue injury. We observed that serum aspartate aminotransferase (AST) levels (Fig. 7C), lung myeloperoxidase (MPO) levels (Fig. 7D), bronchoalveolar lavage (BAL) fluid protein content (data not shown), and intestinal wet/dry ratios (Fig. 7E) were not significantly different between vehicle-treated WT mice and those treated with rhIL-7. Experiments conducted with sham-operated mice did not demonstrate detectable levels of IL-6, bacteremia, or tissue injury. All together, mice treated with rhIL-7 had diminished bacteremia and early increased, but not sustained, inflammation, but not worsened tissue damage, compared to those of vehicle-treated mice.

DISCUSSION

In this study, we tested the hypothesis that IL-7, a potent T-cell antiapoptotic cytokine, would mediate the early innate immune response to sepsis. First, we demonstrated the necessity of αβ and/or γδ T cells for the IL-7-induced increase in survival of septic wild-type mice. Additionally, we show the upregulation of Bcl-2 expression on CD4 T cells and/or γδ T cells following sepsis, the production of IL-17 by these cells, and increased CXCL1/KC accumulation. rhIL-7 treatment increases inflammation and bacterial clearance without changing end-organ tissue injury. Properly regulated neutrophils play an important role in bacterial clearance (32); however, decreased apoptosis and increased half-life may result in increased tissue injury during sepsis (22). During sepsis, an optimal balance among early pathogen clearance, associated inflammation, and end-organ tissue damage will likely allow for a reduction of host morbidity and mortality. As IL-6 has previously been utilized as a surrogate marker for inflammation (42), we evaluated the serum levels of this cytokine at 6 and 24 h. Mice treated with rhIL-7 had significantly higher serum IL-6 levels at 6 h than WT mice, with no difference existing at 24 h (Fig. 7A). Evaluation of bacteremia at 24 h following CLP demonstrated a significantly lower bacterial load in those animals treated with rhIL-7 rather than vehicle (Fig. 7B), consistent with previous findings. We next evaluated general, lung, and intestine tissue injury. We observed that serum aspartate aminotransferase (AST) levels (Fig. 7C), lung myeloperoxidase (MPO) levels (Fig. 7D), bronchoalveolar lavage (BAL) fluid protein content (data not shown), and intestinal wet/dry ratios (Fig. 7E) were not significantly different between vehicle-treated WT mice and those treated with rhIL-7. Experiments conducted with sham-operated mice did not demonstrate detectable levels of IL-6, bacteremia, or tissue injury. All together, mice treated with rhIL-7 had diminished bacteremia and early increased, but not sustained, inflammation, but not worsened tissue damage, compared to those of vehicle-treated mice.

FIG. 6. IL-7 treatment increases the number of, and IL-17 production by, peritoneal γδ T cells following CLP. CLP-operated WT mice were treated with 5 μg human recombinant IL-7 or vehicle at the time of CLP. Flow cytometric analysis was used to enumerate the number of peritoneal γδ T cells producing IL-17 (A) and the intensity of IL-17 expression by peritoneal γδ T cells (B) 3 h after CLP. The sample size was 4 mice/group. (C) Peritoneal lavage fluid obtained 6 h after CLP from WT and TCR γδ-deficient mice treated with IL-7 or vehicle was analyzed by ELISA for IL-17. The sample size was 5 mice/group. (D) Peritoneal lavage fluid obtained 6 h after CLP was analyzed by ELISA for CXCL1/KC. The sample size was 11 to 14 mice/group. Data are expressed as the mean values ± SEM. *, P < 0.05; **, P < 0.01.
induced defective production of IFN-γ (55). Here, we built upon these findings by demonstrating an IL-7-induced increase in peritoneal IFN-γ levels. Increased IFN-γ production has been shown to promote macrophage or endothelial CXCL10/IP-10 expression (3, 19, 31), a ligand for the CXCR3 receptor. We show that this receptor is expressed upon γδ T cells. These results suggest that IL-7 treatment improves the host response to sepsis through the rapid recruitment of γδ T cells to the site of infection, coupled with accelerated γδ T cell-mediated recruitment of neutrophils to the site of infection. All together, these data are summarized in Fig. 8.

The work detailing that rhIL-7 treatment improves the murine host response to sepsis has recently been reported (55), although its effects on lymphocyte apoptosis and proliferation in human diseases such as hepatitis C and cancer stem from ongoing clinical trials (46, 49). At 24 h following CLP, IL-7 treatment significantly increased Bcl-2 expression in splenic CD4 and CD8 T-cell subsets compared to that in wild-type animals and produced a relative change of mRNA abundance in CD4 T cells (55). Additionally, rhIL-7 blunted both splenic and mesenteric lymph node T-cell apoptosis at 24 h following CLP, resulting in significantly elevated numbers of CD4 and CD8 T cells in treated versus WT mice at this time point (55). Clinical findings of decreased Bcl-2 gene expression in septic human patients at 12 and 24 h following diagnosis were previously noted to correlate highly with decreased absolute numbers of CD4 lymphocytes (4, 24). Furthermore, prevention of apoptosis with overexpression of Bcl-2 is known to prevent T-cell apoptosis, providing protection from sepsis-related mor-

FIG. 7. IL-7 treatment mediates serum IL-6 levels, decreases bacteremia, and does not alter tissue injury after CLP. WT mice were subjected to CLP, as indicated in Materials and Methods, and treated with 5 μg human recombinant IL-7 or vehicle at the time of CLP. (A) Sera obtained at the indicated time points were analyzed by ELISA for IL-6. (B) Serum bacterial loads were measured 24 h after induction of sepsis. (C) Serum AST levels were measured 24 h after induction of sepsis. (D) Lungs were harvested at the indicated times after CLP, and MPO was measured. (E) Sections (2 cm) of terminal ileum were obtained at the indicated times following CLP, weighed, and dried as described in Materials and Methods. The sample size was 8 to 11 mice/group. Data are expressed as the mean values ± SEM. *, P < 0.05; ***, P < 0.001.

FIG. 8. Model for IL-7’s role in modulating neutrophil recruitment in sepsis. This figure represents a schematic hypothesis, demonstrating how rhIL-7 treatment, through maintenance of appropriate T-cell immunocompetence, results in enhanced neutrophil recruitment to the site of infection.
The lack of a functional effect on neutrophils following IL-7 in this model assessing the role of neutrophils in sepsis (22). At 24 h may explain the comparable levels of end-organ tissue changes. The rapid return of neutrophil numbers to WT levels is likely responsible for the decreased bacterial load in rhIL-7 treated mice following CLP, suggesting apoptotic signaling in T cells takes place soon after induction of sepsis. One key effect of early T-cell apoptosis in sepsis is reduced immunocompetence through decreased IFN-γ production. The production of IFN-γ by CD4 T cells during sepsis is associated with improved survival, decreased bacterial load, and increased neutrophil functionality (37, 53). Interestingly, we show that IL-7 treatment significantly increases the peritoneal concentration of IFN-γ as early as 3 h following CLP. These data suggest that rhIL-7 treatment upregulates Bcl-2 expression very soon after treatment, such that T-cell apoptosis can be reduced and IFN-γ production can be preserved.

The enhanced production of IFN-γ in rhIL-7-treated mice relative to WT controls exerts downstream effects on both adaptive and innate cells. Gamma interferon-inducible protein 10 (CXCL10/IP-10) is a chemokine secreted by endothelial cells, macrophages, and neutrophils upon stimulation with IFN-γ and serves as a chemoattractant for T lymphocytes (7, 35, 61). It has been suggested that CXCL10/IP-10 plays a distinct role in the recruitment of T cells expressing CXCR3 to sites of inflammation (7), consistent with findings that TCR γδ T cells express CXCR3 and transmigrate upon stimulation with IP-10 (11, 45). Here, we demonstrate that a large percentage of γδ T cells and neutrophils present at the site of infection soon following CLP express CXCR3. Further, septic mice treated with IL-7 had significantly larger amounts of CXCL10/IP-10 at the peritoneum. Consistent with these findings, we observed that rhIL-7 treatment resulted in an elevated number of γδ T cells at the site of infection. All together, we postulate that IL-7 treatment enhanced T-cell IFN-γ production such that CXCL10/IP-10 was increased and γδ T cells entered the site of infection.

After exposure to CXCL10/IP-10, γδ T cells can transmigrate and mediate inflammatory processes in tissue compartments such as the lung and peritoneum. The inflammatory effects of γδ T cells result, in part, from production of the cytokine IL-17 in response to early and sustained stimulation by IL-1β, TLR-2, and IL-23 (1, 38, 43, 50). IL-17 acts upon mesothelial cells to produce CXCL1/KC and CXCL2/MIP-2 (15) and has been shown to be necessary for the promotion of granulopoiesis and neutrophil recruitment in peripheral tissues (14, 62). Here, we show that local and systemic levels of IL-17 are elevated with rhIL-7 treatment following CLP, with a subsequent and complementary increase in CXCL1/KC. Further, elevated IL-17 following rhIL-7 treatment in sepsis is dependent upon the presence of γδ T cells. This demonstrates a sequential and mechanistic pathway through which rhIL-7-mediated attenuation of T-cell dysfunction results in increased neutrophil recruitment to the site of infection following CLP. The elevated number of neutrophils early in the septic course is likely responsible for the decreased bacterial load in rhIL-7-treated mice, even in the absence of neutrophil functionality changes. The rapid return of neutrophil numbers to WT levels at 24 h may explain the comparable levels of end-organ tissue damage seen in these groups, consistent with previous findings in this model assessing the role of neutrophils in sepsis (22).

The lack of a functional effect on neutrophils following IL-7 treatment may further explain the consonant end-organ results in these studies. All together, we speculated that the ability of rhIL-7 to maintain numbers and functionality of CD4 T cells following sepsis resulted in accelerated γδ T-cell recruitment and functionality at the site of infection, ultimately aiding bacterial clearance without worsening tissue damage.

Our data reported here demonstrate that rhIL-7 treatment increased peritoneal IFN-γ levels, IP-10 levels, and CXCR3-expressing γδ T-cell accumulation. However, one limitation to this report is a lack of data verifying that IP-10, through CXCR3, recruits γδ T cells to the peritoneum. While trying to address this, we subjected CXCR3-deficient mice to CLP and found that these mice had significantly increased peritoneal bacterial loads compared to those of WT mice. In addition, neutrophils isolated from these mice demonstrated a decreased phagocytic capacity. Finally, the CXCR3 knockout (KO) had increased numbers of neutrophils and macrophages at the site of infection compared to those of controls. We speculate that the CXCR3-mediated defect in phagocytosis resulted in sustained leukocyte chemotaxis that ultimately confounded the experimental results. Thus, the use of more specific reagents will be needed to fully address this potentially important mechanism.

Sepsis involves a complex interplay between the innate and adaptive immune systems that occurs very early after the onset of disease and not in a delayed fashion, as previously accepted. γδ T cells, through production of IL-17, appear to play a central role in immune response cross talk between the two arms of the immune response. In addition, the existence of cross talk between these two responses suggests that multiple targets for future therapeutic intervention may be available. One such therapeutic target is the cytokine IL-7, shown to play a direct role in prevention of T-cell apoptosis, with subsequent downstream effects resulting in an enhanced innate response to sepsis. Going forward, these insights may play a role in the ultimate production of a viable sepsis therapeutic target that reduces the health care burden imposed by this disease process.

ACKNOWLEDGMENTS

This work was supported in part by National Institutes of Health grants GM72760 (to C.C.C.), GM44118 and GM55194 (to R.S.H.), and AI057753 (to D.A.H.) and by the Alan A. and Edith L. Wolff Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Michel Morre is the CEO of Cytheris Corporation, a company that makes IL-7 for clinical trials. The other authors have no financial conflicts of interest.

REFERENCES


Editor: J. N. Weiser


